Delivery and formulation of engineered nucleic acids
US-2024252645-A1 · Aug 1, 2024 · US
US9255274B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9255274-B2 |
| Application number | US-74385308-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2008 |
| Priority date | Nov 22, 2007 |
| Publication date | Feb 9, 2016 |
| Grant date | Feb 9, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An object of the present invention is to provide a translationally regulatable mRNA which has wider application and can perform specific ON-OFF regulation, an RNA-protein complex specifically bound to the mRNA, and a translational regulatory system. The present invention provides an mRNA having an RNA-protein complex interacting motif-derived nucleotide sequence 5′ to the ribosome-binding site or within the 5′ region of the open reading frame, and an mRNA having a nucleotide sequence complementary to an RNA-protein complex interacting motif-derived nucleotide sequence 5′ to the ribosome-binding site or within the 5′ region of the open reading frame.
Opening claim text (preview).
The invention claimed is: 1. An isolated non-naturally occurring mRNA encoding a protein comprising an RNA-protein complex interacting motif nucleotide sequence incorporated 5′ to a ribosome-binding site in a position 2 to 10 bases distant from the ribosome-binding site or within the 5′ region of an open reading frame, wherein the interacting motif comprises nucleic acid sequence SEQ ID NO:9, wherein an RNA-protein complex of the interacting motif and L7Ae protein has a dissociation constant Kd of approximately 0.1 nM to approximately 1 μM between the motif and L7Ae and the interacting motif interacts with L7Ae protein. 2. An RNA-protein complex comprising an mRNA according to claim 1 and a protein specifically binding to the nucleotide sequence. 3. A translational regulatory kit comprising an mRNA according to claim 1 and a protein specifically binding to the nucleotide sequence. 4. A method for translational regulation of mRNA, comprising contacting the mRNA according to claim 1 with a protein specifically binding to the RNA-protein complex interacting motif nucleotide sequence. 5. An artificial information conversion method which converts input information of an arbitrary substrate protein to output information of an arbitrary target protein using an mRNA according to claim 1 , comprising steps of preparing the mRNA of claim 1 having an open reading frame encoding the arbitrary target protein; and contacting the mRNA with the substrate protein that specifically binds to the RNA-protein complex interacting motif nucleotide sequence. 6. A plasmid vector comprising a nucleic acid sequence encoding an mRNA according to claim 1 . 7. An intracellular translational regulatory kit comprising a first plasmid vector comprising a nucleic acid sequence encoding an mRNA according to claim 1 , and a second plasmid vector comprising a nucleic acid sequence encoding a protein specifically binding to the RNA-protein complex interacting motif nucleotide sequence. 8. The kit according to claim 7 , for regulating protein translation in a human cancer cell.
General methods for enhancing the expression · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.